Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 54, Issue 1, 2001, Pages 31-38

  Marx, Gavin M ^a   Pavlakis, Nicholas ^a   McCowatt, Sally ^a   Boyle, Frances M ^a   Levi, John A ^a   Bell, David R ^a   Cook, Raymond ^a   Biggs, Michael ^a   Little, Nicholas ^a   Wheeler, Helen R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antiangiogenesis; Glioblastoma; Low dose; Neuropathy; Thalidomide; VEGF

Indexed keywords

ANGIOGENIC FACTOR; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUROPATHY; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER; TACHYPHYLAXIS; TOXICITY TESTING; TUMOR VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; FEMALE; GLIOBLASTOMA; HUMANS; LYMPHOKINES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; SURVIVAL; THALIDOMIDE; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035191268     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012554328801     Document Type: Article

References (29)

1. Estimates of the worldwide incidence of twenty-five major cancers in 1990
2. Estimates of the worldwide mortality from twenty-five major cancers in 1990
3. Epidemiology of brain cancer
4. Adjuvant and neoadjuvant treatment for primary brain tumors in adults
5. Treatment of recurrent high grade astrocytoma; Results of a systematic review of 1415 patients
6. What is the evidence that tumors are angiogenesis dependent?
7. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human glioma in vivo
8. Correlation of bFGF expression levels with degree of malignancy and vascularity in human gliomas
9. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer agents
10. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
11. Thalidomide in oncology: The peril and the promise
12. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
13. Thalidomide is an inhibitor of angiogenesis
14. Antitumor activity of thalidomide in refractory multiple myeloma
15. Activity of thalidomide in AIDS-related Kaposi's sarcoma
16. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC)
17. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
18. A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer
19. Phase II study of the anti-angiogenic agent thalidomide with recurrent high-grade gliomas
20. Correlation of measurements of pressure perception using the pressure-specified sensory device with electrodiagnostic testing
21. Chemotherapy induced peripheral neuropathy
22. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
23. Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high-grade gliomas
24. Thalidomide induced peripheral neuropathy: A prospective clinical, neurophysiological and pharmacogenetic evaluation
25. Thalidomide-induced neuropathy and genetic differences in drug metabolism
26. Vascular endothelial growth factor (VEGF) is released from platelets during clotting: Implications for measurement of circulating VEGF levels in clinical disease
27. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?
28. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen?
29. MRI enhancement and microvascular density in gliomas: Correlation with tumor cell proliferation